| Date Filed | Type | Description |
| 10/04/2023 |
SC 13D/A
| Roivant Sciences Ltd. reports a 55.3% stake in Immunovant, Inc. |
| 09/29/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 09/28/2023 |
8-K
| Quarterly results |
| 09/28/2023 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
| 09/26/2023 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
| 09/26/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/23/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 04/05/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/27/2023 |
8-K
| Investor presentation |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/03/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/03/2023 |
10-Q
| Quarterly Report for the period ended December 31, 2022 |
| 02/03/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 01/09/2023 |
8-K
| Quarterly results |
| 12/08/2022 |
8-K
| Quarterly results |
| 12/05/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 12/02/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/04/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/04/2022 |
8-K
| Quarterly results |
| 10/05/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 10/04/2022 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, among the Company and SVB Securities LLC",
"Opinion of Cooley LLP",
"Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock New York, October 4, 2022 - Immunovant, Inc. , a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at an offering price of $6.00 per share. Investors who have agreed to purchase shares in the offering include Logos Capital, Deep Track Capital, Frazier Life Sciences, TCGX, BVF Partners L.P., Commodore Capital, and an undisclosed healthcare specialist fund. Before deducting the underwriting discounts and commissions and offering expenses, the company expects to receive total gross proceeds of $75.0 million. The company intends to use the net proceeds f..." |
|
| 09/28/2022 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 09/07/2022 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 08/19/2022 |
8-K
| Quarterly results |
| 08/05/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/05/2022 |
8-K
| Quarterly results |
| 06/30/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 06/30/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 06/08/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 06/08/2022 |
10-K
| Annual Report for the period ended March 31, 2022 |
| 06/08/2022 |
8-K
| Quarterly results |
| 03/30/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
|